Skip to main content
OpenTrials
Completed

NCT Number: NCT05073510

Clinical Evaluation of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease

This is a BlueDop Vascular Expert System (BVE) Post-Market Clinical Follow-Up (PMCF) study. The primary objective of the study is to assess the clinical applicability and diagnostic accuracy of the BVE device in subjects who require an arterial duplex test due to suspected peripheral arterial disease (PAD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Los Madroños, Brunete, Madrid, Spain

Loading trial locations.

About this study

The BVE device is intended to assess mean peripheral pressure, vascular reserve, Cuff free Ankle Brachial Index (ABIm), and assess the presence or absence of hemodynamically significant arterial disease. By converting Doppler shifts to a blood pressure measurement, BVE can be used to monitor PAD in a non-invasive manner without confounding by arterial calcification.

This is a post-market, interventional, prospective, multi-center, open-label, non-randomized, single-arm clinical investigation designed to evaluate the clinical equivalence of BVE to arterial Duplex in a group of patients referred for evaluation of PAD of the limbs when performed by a vascular specialist. Moreover, the evaluation of the clinical performance including inter-operator variability and BVE non-diagnostic rate will be also carried out as exploratory variables.

  • Primary objective:

Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to arterial duplex ultrasound in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.

  • Secondary objectives:

Evaluate the clinical equivalence (assessment of accuracy) of BVE as binary result (either presence or absence of significant peripheral arterial disease) compared to ankle brachial pressure index (ABPI) in a group of patients referred for evaluation of PAD of the lower limbs when performed by a vascular specialist.

Assess the safety of the BVE device.

  • Exploratory objectives:

Evaluation of the BVE System for clinical performance including time needed to perform BVE, inter-operator variability and number of BVE non-diagnostic tests.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must provide written informed consent prior to any clinical investigation related procedure.
  • At least 18 years of age.
  • Referred for duplex ultrasound of the lower limb (s) with suspected or previous history of peripheral arterial disease
  • Must have an ABPI performed as part of the assessment
  • Able to obtain a brachial cuff blood pressure reading
  • Must have a valid ankle duplex ultrasound measurement at the Posterior Tibial Artery (PTA) and Dorsalis Pedis Artery (DPA)

Exclusion criteria

  • Subject is currently participating in another clinical investigation or has participated in another clinical investigation in the past 30 days prior to the start of the present study;
  • Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  • Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness;
  • Inability or refusal to give informed consent
  • Lower extremity wound or compromised skin of the legs that prevents access to the studied arteries

Treatment and study plan

BVE

Device

Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)

Primary outcomes

  1. Determination of Presence or Absence of Significant PAD With BVE and Arterial Duplex

    Time frame: 1 day

    Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of the arterial duplex.

    Significant PAD is established with Duplex ultrasound when peak systolic velocity ratio (PSVR) is greater than 3 for any one level, or, if patients have multi-level disease, PSVR ≥ 2 at more than one level (i.e. sfa, pop)

Secondary outcomes

  1. Determination of Presence or Absence of Significant PAD With BVE and ABPI

    Time frame: 1 day

    Evaluation of clinical equivalence through a binary result (either presence or absence of significant PAD) in BVE compared to a binary summary of ABPI.

    Significant PAD is established when ABPI index is <0.8.

  2. Number and Risk-classification of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: 1 day

    Evaluation of BVE safety through the assessment of the risk and occurrence rates of AEs and SAEs

Other outcomes

  1. Time Spent for Arterial Duplex, BVE and ABPI Vascular Assessment

    Time frame: 1 day

    Comparison of the time to perform a vascular assessment using arterial duplex, BVE, and ABPI (when available).

  2. Determination of Presence or Absence of Significant PAD With BVE by Vascular and Non-vascular Experts

    Time frame: 1 day

    Evaluation of clinical equivalence of BVE testing performed by staff specifically trained on BVE who are not vascular technologists/specialists compared to BVE testing performed by vascular technologists/specialists.

  3. BVE Non-diagnostic Rate

    Time frame: 1 day

    Number of patients and/or limbs that could not be assessed by BVE.

Sponsors and collaborators

Lead sponsor

BlueDop Medical LTD

Industry

Collaborators

  • AKRN Scientific Consulting, S.L.

Registry information

Official study title

A Prospective, Multicenter, Nonrandomized, Open-label, Single-arm Study of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Oct 11, 2021
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.